Zydus Wellness Ltd

- Currently, Zydus Wellness has taken a bridge loan of GBP 240 million with a 15-month tenure at an interest rate of 5% for the Comfort Click acquisition. - There is no immediate plan to raise equity for repaying this bridge loan. - The company may consider replacing the bridge loan with a mix of equity or borrowing in the next couple of quarters. - Decisions regarding fundraising will be made as the situation evolves, but for now, they will continue with the bridge loan.

- There are no specific mentions of current or future capex or capital investments in detail. - The company is focused on expanding distribution, aiming to increase direct reach from around 6.2 lakh outlets to 3 million, then 3.5 million and beyond. - Strategic investments include acquisitions like Comfort Click to enter and expand in international markets (Europe and U.S.). - They are investing in expanding general trade and quick commerce channels domestically. - There are plans to evaluate and possibly launch new products in the RiteBite portfolio, such as protein powders and fitness SKUs. - Integration efforts are ongoing for acquired businesses (e.g., RiteBite Max Protein) to leverage broader distribution. - Marketing and advertising spends have increased due to inclusion of RiteBite and Max Protein as well as acquisition-related activities, indirectly reflecting strategic investment in brand building.

- Zydus Wellness targets double-digit growth over the next 3 to 5 years, driven by multi-category, multichannel, and multi-geography strategies. - Distribution expansion is a key growth lever, with plans to increase direct reach from 6.2 lakh outlets to 3 million and then 3.5 million outlets. - The company sees growth opportunities in both legacy and new products like RiteBite and Comfort Click, with efforts to expand in existing and new international markets including the U.S. - Seasonal brand sales, such as Nycil and Glucon-D, are expected to revive in Q4, contributing to margin improvement and revenue growth. - E-commerce is growing, with significant contribution for brands like RiteBite and Complan, supporting broader market share gains. - Comfort Click is expected to continue high double-digit growth in international markets, with a strategic focus on both growth and operational efficiency.

- Zydus Wellness targets achieving a 17%-18% EBITDA margin over the next 2 years through gross margin improvements and operating leverage as scale increases. - Despite short-term challenges in seasonal categories (Nycil, Glucon-D), the company expects margin trajectory to improve as normalcy returns in Q3 and Q4. - Over the next 3 to 5 years, the company aims for double-digit growth driven by multiple categories, channels, and geographies rather than reliance on a few blockbusters. - Comfort Click acquisition is expected to contribute to earnings growth without margin pressure from international expansion, with high double-digit growth potential. - RiteBite Max Protein business has exceeded growth and profitability estimates since acquisition, indicating strong future earnings contribution. - The company is optimistic about volume and sales growth driving future profitability rather than just margin expansion. - Focus on expanding distribution, e-commerce, and international markets supports sustained long-term growth in earnings and EPS.

The transcript of Zydus Wellness Limited's earnings call on November 5, 2025, does not explicitly mention details about the current or expected order book or pending orders. However, key points related to growth and distribution include: - Direct distribution reach currently at over 6.2 lakh outlets, aiming to increase overall availability to 3 million outlets, then 3.5 million and beyond. - Expansion in multiple channels including chemist, general trade (kirana stores), quick commerce, and e-commerce. - International expansion underway, including Comfort Click's growth and foray into the U.S. and Europe. - Strategic focus on growing market share and expanding consumer base through multiple product categories. - Ongoing evaluation of new products for the RiteBite brand. - No specific figures or commentary on order book or pending orders disclosed in the call. Hence, there is no detailed data on order book or pending orders provided in this document.